[New guideline for the management of hyperlipidemia according to patient category and global risk chart]

Area of Science:

• Cardiovascular Epidemiology
• Preventive Cardiology
• Clinical Risk Prediction

Context:

• Existing coronary heart disease (CHD) risk charts, like the Framingham Study, lack validity for Japanese populations.
• There is a need for large-scale prospective studies to assess CHD risk factors in Japan.
• The Japan Lipid Intervention Trial (J-LIT) was initiated to address this gap in a clinical setting.

Purpose:

• To develop and validate accurate, easy-to-use risk charts for predicting coronary events in the Japanese population.
• To assess the relationship between established coronary risk factors and the incidence of CHD in Japan.
• To provide individualized risk factor management tools for Japanese patients.

Summary:

• The 6-year Japan Lipid Intervention Trial (J-LIT) prospectively studied simvastatin therapy for mild hypercholesterolemia.
• Major coronary events were recorded in primary (47,294 patients) and secondary (5,127 patients) prevention cohorts.
• New risk charts were created, showing lower absolute risks than the Framingham formula, for both primary and secondary coronary events in Japanese patients.

Impact:

• The J-LIT charts provide accurate absolute and relative risk predictions tailored to Japanese individuals.
• These charts facilitate individualized risk factor management, potentially improving CHD prevention strategies in Japan.
• The study contributes crucial data to cardiovascular epidemiology for East Asian populations.